FIELD: biotechnology; medicine.
SUBSTANCE: mutant F protein of respiratory syncytial virus (RSV) having a mutation, where the mutation is a substitution of leucine corresponding to leucine at position 141 of the amino acid sequence SEQ ID NO: 1, or the leucine corresponding to the leucine at position 142 with a cysteine, and the replacement of the leucine corresponding to the leucine at position 373 with a cysteine, followed by the formation of a disulfide bond between the cysteines. The invention also relates to a fusion protein, a mutant protein multimer, an immunogenic product of particulate or immunogen, a pharmaceutical composition and a vaccine containing this mutant protein, the respiratory syncytial virus F protein.
EFFECT: effective treatment of RS viral infection.
39 cl, 35 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| F RSV PROTEIN MUTANTS | 2016 |
|
RU2788403C2 |
| PROTEIN F RSV MUTANTS | 2016 |
|
RU2723039C2 |
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| RSV PROTEINS IN PRE-CONFLUENCE CONFORMATION AND USE THEREOF | 2014 |
|
RU2761631C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
